About this trial
Gestational diabetes mellitus (GDM), defined as hyperglycemia with blood glucose values above normal but below those diagnostic of DM, and iron deficiency (ID) with or without anemia (IDA) are common during pregnancy. Both disease patterns are associated with an increased risk of complications during pregnancy and at delivery and may have a variety of negative effects on different aspects of child development. Thus, GDM and ID/IDA during pregnancy should be prevented.
Whether iron supplementation with high oral doses acutely increases hepcidin during pregnancy, and whether this acute iron-induced increase in hepcidin decreases insulin sensitivity, is uncertain.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
week of pregnancy 24-28
pre-pregnancy BMI <27.5kg/m2
singleton pregnancy
Hb > 8.0 g/dl
Disqualifiers
iron infusion within the past 6 months
severely anemic Hb<8.0g/dl
acute or chronic disease
long-term medication
Trial design
Parallel
Treatments tested in this trial
100mg iron fumarate
Dietary supplement100mg iron fumarate b.i.d. for 4 consecutive days
Burgerstein Schwangerschaft & Stillzeit
Dietary supplementcontains 30 mg iron fumarate, given on 14 consecutive days
Treatment groups
Trial outcomes
Primary outcomes
Serum hepcidin
Serum hepcidin
Serum hepcidin
Serum hepcidin
Secondary outcomes
Serum ferritin
Serum ferritin
Serum ferritin
Serum ferritin
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Swiss Federal Institute of Technology
Lead sponsor
University Hospital, Zürich
Collaborator